BOZEN, SUD-TYROL, Italy, November 12 /PRNewswire/ -- Health Robotics today announced that Innomed/BioRobotics, on the heels of its prior market success with Oncology Surgery robots, has exclusively selected Health Robotics' CytoCare(TM) Robot to reach its objective to become the gold standard for Oncology Robotics IV Admixtures in the Republic of Korea and synergistically provide an end-to-end Cancer Robotics solution.
We are very pleased to reach 100% territorial coverage for CytoCare in Asia-Pacific. This new partnership culminates a great year for Health Robotics' CytoCare adoption and unprecedented market success versus our competition, on the heels of similar new partnerships signed this Summer and Fall in Oceania, China, Taiwan, and South East Asia. In these difficult economic times and at a moment where our competitors are in retreat and total disarray, we have increased our lead in product superiority, expanded our reach worldwide, and are now posed to reap benefits in years to come. We welcome BioRobotics to our family of strategic channel partners and look forward to host them next week, along with more than twenty (20) worldwide partners at Health Robotics' First Annual Partner Training in Trieste, Italy, stated Werner Rainer, Health Robotics' CEO.
CytoCare is the world's first and only robotic system designed for the safe and sterile preparation of patient-specific hazardous IV Admixtures for Chemotherapy, Monoclonal Antibody Therapy, and Gene Therapy. While other companies have for many years made promises of robotic IV automation products and even showcased staged smoke and mirrors marketing demonstrations of competing solutions that were supposed to exist as far back twenty years ago, the fact remains that CytoCare is the only available solution that currently exists anywhere in the world to automatically compound and prepare ready-to-administer hazardous IV Admixtures, and that has been proven to work in a live hospital pharmacy environment, instead of just marketing brochures and theatrical shows.
We are delighted that Health Robotics has given us this great opportunity as their exclusive strategic partner in our core market of Korea. CytoCare, the world's only real Oncology IV Admixtures Robot in existence, represents an ideal complement to BioRobotics' medical portfolio of Oncology Robotics' products and services, including Intuitive Surgical's daVinci(R) Surgery Robot. Just like Device Technologies Australia and PinnacleMed, I was very impressed with Health Robotics' technology and have received excellent references from other Asia-Pacific based daVinci(R) Surgery Robot's distribution partners, with whom we maintain regular contact. My contract negotiation meetings with Gaspar DeViedma last week were very productive and led to the execution of this very important milestone for our company, stated Bum Kyo Lee, CEO of BioRobotics.
Founded in 1995, Innomed/BioRobotics is currently the leading medical robotics supplier and the second largest medical importing business in the Republic of Korea with US $27M import volume during the year 2008. The company originally started in the Aesthetic laser surgery and Cryosurgery medical sectors and further expanded into robotic surgery in 2005. In only 4 years since the launch of Oncology Robotics in its core market, BioRobotics has already achieved twenty-four (24) installations of the daVinci(R) Surgical robot in the Republic of Korea. For more information, please visit: http://www.biorobotics.co.kr/
About Health Robotics:
Health Robotics is the global leading supplier of life-critical intra-venous medication preparation, compounding, and dispensing Robots, providing healthcare facilities in four continents with robotics technology and software automation solutions. The world-leading solutions CytoCare [hazardous IVs], i.v.STATION [non-hazardous IVs], i.v.SOFT [workflow engine] and the future development of TPNstation constitute the main building blocks of the company's vision to architect the I.V. Room of the Future on or before the year 2011. These Robots and software automation solutions have and will greatly contribute to ease global hospitals' growing pressures to improve patient safety through the effective and efficient production of sterile, accurate, and ready-to-administer IVs, to eliminate life-threatening drug-exchange errors, to decrease other medication errors and sterility risks, and to work more efficiently, improve situational awareness of the IV Medication Management processes across the continuum of care, reduce the generational gap between rising patient volume/acuity and scarce pharmacy personnel, increase throughput, reduce waste, and contain costs. For more information, please visit http://www.health-robotics.com
 Am J Hosp Pharm 46(11): 2286-93 1989
For additional information, please contact: Health Robotics S.r.l Gaspar G. DeViedma, General Counsel Altmanstrasse 9A, Bozen, Sud-Tyrol, Italy-39100 USA: +1-609-980-7976 EUROPE: +39-346-963-4934 email@example.com BIOROBOTICS Bum Kyo Lee, CEO 5F 5-36 Hyochang-dong, Yongsan-ku, Seoul, Korea Phone: +82-27015266 firstname.lastname@example.org
SOURCE: Health Robotics
CONTACT: For additional information, please contact: Health RoboticsS.r.l, Gaspar G. DeViedma, General Counsel, Altmanstrasse 9A, Bozen,Sud-Tyrol, Italy-39100, USA: +1-609-980-7976, EUROPE: +39-346-963-4934,email@example.com . BIOROBOTICS: Bum Kyo Lee, CEO, 5F5-36 Hyochang-dong, Yongsan-ku, Seoul, Korea, Phone: +82-27015266,firstname.lastname@example.org